6 Einträge |
Seite 1 / 1
![]() |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. |
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG |
Journal of the peripheral nervous system : JPNS. 2019 Jan 23. doi: 10.1111/jns.12306 |
PMID: 30672664 |
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). |
Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E |
The oncologist. 2019 Mar 13. pii: theoncologist.2018-0787. doi: 10.1634/theoncologist.2018-0787 |
PMID: 30867244 |
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. |
Procopio G, Bamias A, Schmidinger M, Hawkins R, Sánchez AR, Estevez SV, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Rodriguez CS, Jonasch E |
Clinical genitourinary cancer. pii: S1558-7673(19)30044-8. doi: 10.1016/j.clgc.2019.01.018 |
PMID: 31196680 |
Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study). |
Procopio G, Bamias A, Schmidinger M, Hawkins R, Rodriguez Sanchez A, Vazquez S, Srihari N, Kalofonos H, Bono P, Pisal C, Hirschberg Y, Dezzani L, Ahmad Q, Suarez Rodriguez C, Jonasch E |
Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)49273-9. doi: 10.1093/annonc/mdy283.093 |
PMID: 32136729 |
Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy Induced Peripheral Neurotoxicity. |
Alberti P, Bernasconi DP, Cornblath DR, Jose Merkies IS, Park SB, Velasco R, Bruna J, Psimaras D, Susanne K, Pace A, Dorsey SG, Argyriou AA, Kalofonos HP, Briani C, Schenone A, Faber CG, Mazzeo A, Grisold W, Valsecchi M, Cavaletti G |
Neurology. 2021 Jun 2. pii: WNL.0000000000012300. doi: 10.1212/WNL.0000000000012300 |
PMID: 34078718 |
6 Einträge |
Seite 1 / 1
![]() |